Morgan Stanley lowered the firm’s price target on AstraZeneca (AZN) to 13,700 GBp from 14,500 GBp and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca considering moving more production to U.S., Pharmaphorum reports
- AstraZeneca: Strong Buy Rating Backed by Oncology Growth and Promising Pipeline
- AstraZeneca’s Strong EPS Performance and Strategic Developments Justify Buy Rating
- AstraZeneca Reports Strong Q1 2025 Growth
- AstraZeneca’s Earnings Call: Strong Growth Amid Challenges